EGF and cancer: Importantly, through the interaction with EGF pathway, hydralazine may disrupt several cancer cell networks: by means of SRC, it may lead to a decrease in motility and invasion of tumor cells, through AKT, downregulate neoangiogenesis and increase apoptosis, and, finally, through, MAP kinase pathway, decrease tumor cell proliferation.